Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.
Mark W. Ward, BA
Advertisement
Articles by Mark W. Ward, BA
The antihyperglycemic therapeutic class will continue to be a major contributor to prescription drug trends in 2011 and beyond.
Advertisement
Latest Updated Articles
- 2010 Drug Utilization and Cost Trends for Antidiabetic Agents
Published: February 4th 2011 | Updated:
- Early View of Ampyra and Gilenya Use by MS Patients
Published: December 9th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Accelerated Approval of Cancer Drugs: Benefit or Burden?
2
FDA, HHS Move to Accelerate Biosimilar Approvals
3
Pharmacists Lead the Way in Evolving CAR T-Cell and Bispecific Antibody Therapy Management
4
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
5
